Updated Biomarker Analysis (BRAF and RAS Mutations) From the Phase 3 SELECT Study of Lenvatinib (LEN) in Radioiodine-Refractory Differentiated Thyroid Cancer (RR-DTC)
Thyroid World Congress ePoster Library. Tahara M. 06/22/19; 272140; 205
Makoto Tahara
Makoto Tahara
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Background: LEN is an oral multikinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. In the Ph3 SELECT trial of LEN versus placebo in patients with RR-DTC, LEN significantly prolonged median progression-free survival (mPFS).1 This exploratory post hoc biomarker analysis of SELECT investigated whether genomic mutations in BRAF and/or RAS were associated with improved efficacy outcomes in LEN-treated patients.

 

Methods: Archival tumor tissues were collected (if available) from 183/392 patients enrolled in SELECT (LEN, n=123/261; placebo n=60/131). Tissues were subsequently analyzed for BRAF (V600E) and NRAS/KRAS/HRAS (RAS) mutation and efficacy outcomes determined for LEN-treated patients.  

 

Results: LEN-treated patients with a BRAF mutation (n=26/123; 21%) compared with wildtype BRAF (n=97/123; 79%) had longer mPFS (36.8 vs 16.6 months, HR=0.67, 95%CI: 0.37-1.20), median overall survival (mOS: 56.4 vs 39.6 months, HR=0.69, 95%CI: 0.37-1.28) and median duration of response (mDOR: 35.2 vs 25.8 months). The overall response rate (ORR) for patients with BRAF-mutations vs wildtype was 53.8% vs 67.0%. Patients with RAS mutation (n=34/122; 28%) compared with wildtype (n=88/122; 72%) had mPFS of 17.2 vs 24.3 months (HR=0.75, 95%CI: 0.44-1.30), mOS of 44.3 vs 39.6 months (HR=0.82, 95%CI: 0.48-1.41), mDOR of 30.0 vs 30.5 months, and ORR of 70.6% vs 61.4%. Three patients had both BRAF and RAS mutations.

 

Conclusions: In this exploratory post hoc biomarker analysis from SELECT, LEN-treated patients with BRAF or RAS mutations had nominally longer mOS compared with those with wildtype BRAF or RAS. Further research is warranted in patients with RR-DTC and BRAF or RAS mutation.

 


Background: LEN is an oral multikinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. In the Ph3 SELECT trial of LEN versus placebo in patients with RR-DTC, LEN significantly prolonged median progression-free survival (mPFS).1 This exploratory post hoc biomarker analysis of SELECT investigated whether genomic mutations in BRAF and/or RAS were associated with improved efficacy outcomes in LEN-treated patients.

 

Methods: Archival tumor tissues were collected (if available) from 183/392 patients enrolled in SELECT (LEN, n=123/261; placebo n=60/131). Tissues were subsequently analyzed for BRAF (V600E) and NRAS/KRAS/HRAS (RAS) mutation and efficacy outcomes determined for LEN-treated patients.  

 

Results: LEN-treated patients with a BRAF mutation (n=26/123; 21%) compared with wildtype BRAF (n=97/123; 79%) had longer mPFS (36.8 vs 16.6 months, HR=0.67, 95%CI: 0.37-1.20), median overall survival (mOS: 56.4 vs 39.6 months, HR=0.69, 95%CI: 0.37-1.28) and median duration of response (mDOR: 35.2 vs 25.8 months). The overall response rate (ORR) for patients with BRAF-mutations vs wildtype was 53.8% vs 67.0%. Patients with RAS mutation (n=34/122; 28%) compared with wildtype (n=88/122; 72%) had mPFS of 17.2 vs 24.3 months (HR=0.75, 95%CI: 0.44-1.30), mOS of 44.3 vs 39.6 months (HR=0.82, 95%CI: 0.48-1.41), mDOR of 30.0 vs 30.5 months, and ORR of 70.6% vs 61.4%. Three patients had both BRAF and RAS mutations.

 

Conclusions: In this exploratory post hoc biomarker analysis from SELECT, LEN-treated patients with BRAF or RAS mutations had nominally longer mOS compared with those with wildtype BRAF or RAS. Further research is warranted in patients with RR-DTC and BRAF or RAS mutation.

 


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings